Exec team behind $165M gene therapy acquisition back with another Nationwide Children’s spinout

Clarametyx Biosciences Inc. launched in Columbus this week with $3 million in seed funding toward its first application: treating hospital-acquired infections by attacking the “biofilm” that helps bacteria resist antibiotics.

Click here to read the complete story.

Story excerpt provided by Columbus Business First.

Written by Carrie Ghose.

Originally published May 11, 2020.